246 related articles for article (PubMed ID: 22752967)
1. Direct and indirect involvement of microRNA-499 in clinical and experimental cardiomyopathy.
Matkovich SJ; Hu Y; Eschenbacher WH; Dorn LE; Dorn GW
Circ Res; 2012 Aug; 111(5):521-31. PubMed ID: 22752967
[TBL] [Abstract][Full Text] [Related]
2. Cardiac Disease Status Dictates Functional mRNA Targeting Profiles of Individual MicroRNAs.
Matkovich SJ; Dorn GW; Grossenheider TC; Hecker PA
Circ Cardiovasc Genet; 2015 Dec; 8(6):774-84. PubMed ID: 26553694
[TBL] [Abstract][Full Text] [Related]
3. The H19 long noncoding RNA is a novel negative regulator of cardiomyocyte hypertrophy.
Liu L; An X; Li Z; Song Y; Li L; Zuo S; Liu N; Yang G; Wang H; Cheng X; Zhang Y; Yang X; Wang J
Cardiovasc Res; 2016 Jul; 111(1):56-65. PubMed ID: 27084844
[TBL] [Abstract][Full Text] [Related]
4. Regulation of cardiac microRNAs by cardiac microRNAs.
Matkovich SJ; Hu Y; Dorn GW
Circ Res; 2013 Jun; 113(1):62-71. PubMed ID: 23625950
[TBL] [Abstract][Full Text] [Related]
5. Cardiac hypertrophy and dysfunction induced by overexpression of miR-214 in vivo.
Yang T; Gu H; Chen X; Fu S; Wang C; Xu H; Feng Q; Ni Y
J Surg Res; 2014 Dec; 192(2):317-25. PubMed ID: 25085702
[TBL] [Abstract][Full Text] [Related]
6. miR-146a Suppresses SUMO1 Expression and Induces Cardiac Dysfunction in Maladaptive Hypertrophy.
Oh JG; Watanabe S; Lee A; Gorski PA; Lee P; Jeong D; Liang L; Liang Y; Baccarini A; Sahoo S; Brown BD; Hajjar RJ; Kho C
Circ Res; 2018 Aug; 123(6):673-685. PubMed ID: 30355233
[TBL] [Abstract][Full Text] [Related]
7. A human 3' miR-499 mutation alters cardiac mRNA targeting and function.
Dorn GW; Matkovich SJ; Eschenbacher WH; Zhang Y
Circ Res; 2012 Mar; 110(7):958-67. PubMed ID: 22374132
[TBL] [Abstract][Full Text] [Related]
8. MicroRNA-133a protects against myocardial fibrosis and modulates electrical repolarization without affecting hypertrophy in pressure-overloaded adult hearts.
Matkovich SJ; Wang W; Tu Y; Eschenbacher WH; Dorn LE; Condorelli G; Diwan A; Nerbonne JM; Dorn GW
Circ Res; 2010 Jan; 106(1):166-75. PubMed ID: 19893015
[TBL] [Abstract][Full Text] [Related]
9. Targeting the highly abundant circular RNA circSlc8a1 in cardiomyocytes attenuates pressure overload induced hypertrophy.
Lim TB; Aliwarga E; Luu TDA; Li YP; Ng SL; Annadoray L; Sian S; Ackers-Johnson MA; Foo RS
Cardiovasc Res; 2019 Dec; 115(14):1998-2007. PubMed ID: 31114845
[TBL] [Abstract][Full Text] [Related]
10. GATA4 expression is primarily regulated via a miR-26b-dependent post-transcriptional mechanism during cardiac hypertrophy.
Han M; Yang Z; Sayed D; He M; Gao S; Lin L; Yoon S; Abdellatif M
Cardiovasc Res; 2012 Mar; 93(4):645-54. PubMed ID: 22219180
[TBL] [Abstract][Full Text] [Related]
11. MiR-378 controls cardiac hypertrophy by combined repression of mitogen-activated protein kinase pathway factors.
Ganesan J; Ramanujam D; Sassi Y; Ahles A; Jentzsch C; Werfel S; Leierseder S; Loyer X; Giacca M; Zentilin L; Thum T; Laggerbauer B; Engelhardt S
Circulation; 2013 May; 127(21):2097-106. PubMed ID: 23625957
[TBL] [Abstract][Full Text] [Related]
12. Pharmacological Silencing of MicroRNA-152 Prevents Pressure Overload-Induced Heart Failure.
LaRocca TJ; Seeger T; Prado M; Perea-Gil I; Neofytou E; Mecham BH; Ameen M; Chang ACY; Pandey G; Wu JC; Karakikes I
Circ Heart Fail; 2020 Mar; 13(3):e006298. PubMed ID: 32160771
[TBL] [Abstract][Full Text] [Related]
13. Overexpression of miR-223 Tips the Balance of Pro- and Anti-hypertrophic Signaling Cascades toward Physiologic Cardiac Hypertrophy.
Yang L; Li Y; Wang X; Mu X; Qin D; Huang W; Alshahrani S; Nieman M; Peng J; Essandoh K; Peng T; Wang Y; Lorenz J; Soleimani M; Zhao ZQ; Fan GC
J Biol Chem; 2016 Jul; 291(30):15700-13. PubMed ID: 27226563
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic Delivery of miR-148a Suppresses Ventricular Dilation in Heart Failure.
Raso A; Dirkx E; Philippen LE; Fernandez-Celis A; De Majo F; Sampaio-Pinto V; Sansonetti M; Juni R; El Azzouzi H; Calore M; Bitsch N; Olieslagers S; Oerlemans MIFJ; Huibers MM; de Weger RA; Reckman YJ; Pinto YM; Zentilin L; Zacchigna S; Giacca M; da Costa Martins PA; López-Andrés N; De Windt LJ
Mol Ther; 2019 Mar; 27(3):584-599. PubMed ID: 30559069
[TBL] [Abstract][Full Text] [Related]
15. Exploring miRNA-mRNA regulatory network in cardiac pathology in Na
Xue J; Zhou D; Poulsen O; Hartley I; Imamura T; Xie EX; Haddad GG
Physiol Genomics; 2018 Oct; 50(10):846-861. PubMed ID: 30029588
[TBL] [Abstract][Full Text] [Related]
16. Sex differences in response to miRNA-34a therapy in mouse models of cardiac disease: identification of sex-, disease- and treatment-regulated miRNAs.
Bernardo BC; Ooi JY; Matsumoto A; Tham YK; Singla S; Kiriazis H; Patterson NL; Sadoshima J; Obad S; Lin RC; McMullen JR
J Physiol; 2016 Oct; 594(20):5959-5974. PubMed ID: 27270487
[TBL] [Abstract][Full Text] [Related]
17. MicroRNA-19a/b-3p protect the heart from hypertension-induced pathological cardiac hypertrophy through PDE5A.
Liu K; Hao Q; Wei J; Li GH; Wu Y; Zhao YF
J Hypertens; 2018 Sep; 36(9):1847-1857. PubMed ID: 29664809
[TBL] [Abstract][Full Text] [Related]
18. Overexpression of microRNA-99a Attenuates Cardiac Hypertrophy.
Li Q; Xie J; Wang B; Li R; Bai J; Ding L; Gu R; Wang L; Xu B
PLoS One; 2016; 11(2):e0148480. PubMed ID: 26914935
[TBL] [Abstract][Full Text] [Related]
19. MicroRNA-451 exacerbates lipotoxicity in cardiac myocytes and high-fat diet-induced cardiac hypertrophy in mice through suppression of the LKB1/AMPK pathway.
Kuwabara Y; Horie T; Baba O; Watanabe S; Nishiga M; Usami S; Izuhara M; Nakao T; Nishino T; Otsu K; Kita T; Kimura T; Ono K
Circ Res; 2015 Jan; 116(2):279-88. PubMed ID: 25362209
[TBL] [Abstract][Full Text] [Related]
20. Overexpression of miR-142-3p improves mitochondrial function in cardiac hypertrophy.
Liu BL; Cheng M; Hu S; Wang S; Wang L; Tu X; Huang CX; Jiang H; Wu G
Biomed Pharmacother; 2018 Dec; 108():1347-1356. PubMed ID: 30372837
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
